• SENSEX
    NIFTY 50
Healthcare

Government exempts Meril's new coronary stent MeRes 100 from price control

Updated : February 29, 2020 04:41 PM IST

The company has got an exemption for its product MeRes100TM BRS - Sirolimus-eluting bioabsorbable vascular scaffold system from NPPA.
The company said it will start commercial production of the stent in a couple of months.
An extensively researched innovation, MeRes100 BRS is backed by three-year efficacy and safety clinical trial data, and has received eight patents worldwide.
Government exempts Meril's new coronary stent MeRes 100 from price control

You May Also Like

Live TV
Advertisement